With Jakafi's patent cliff looming, Incyte looks to 2025 launches to bulk up revenue by decade's end
Fierce Pharma
OCTOBER 29, 2024
Incyte’s blockbuster JAK inhibitor Jakafi has been driving the company’s sales for years now, with this quarter being no different. | Meanwhile, the company also scrapped plans to expand its topical JAK Opzelura into two other skin disorders.
Let's personalize your content